benefit 1
highdose 1
daunorubicin 1
aml 1
induction 1
extends 1
across 1
cytogenetic 1
molecular 1
groups 1
phase 1
ii 1
randomized 1
trial 2
comparing 1
standard 1
low 1
dose 1
rituximab 1
combined 1
alemtuzumab 1
initial 1
treatment 1
progressive 1
chronic 1
lymphocytic 1
leukemia 1
older 1
patients 1
ecogacrin 1
cancer 1
research 1
group 1
e 1
hematopoietic 1
cell 1
transplantation 1
outcomes 1
monosomal 1
karyotype 1
myeloid 1
malignancies 1
